Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
DB09298InvestigationalSmall molecule
Silibinin is a flavonolignan with hepatoprotective effects used to treat toxic liver damage and as an adjunct in the management of chronic conditions such as cirrhosis and hepatitis. Silibinin is the major active constituent of silymarin, a standardized extract of the milk thistle seeds, containing a mixture of flavonolignans consisting of silibinin, isosilibinin, silicristin, silidianin and others.
- Primary indication
- Currently being tested as a treatment of severe intoxications with hepatotoxic substances, such as death cap (Amanita phalloides) poisoning.Curator reviewed · 14 structured indications
- Formula / weight
- C25H22O10 · 482.441 g/mol (avg)
- Also known as
- Silibinin A · Silybin · Silybin A · Silymarin I
Resolves to
Clinical / RWD
Structure
InChIKey
SEBFKMXJBCUCAI-HKTJVKLFSA-NSMILES[H][C@@]1(OC2=C(O[C@@H]1CO)C=CC(=C2)[C@@]1([H])OC2=C(C(O)=CC(O)=C2)C(=O)[C@@H]1O)C1=CC(OC)=C(O)C=C1Targets
What you can answer from here — as of July 17, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4TransportersSubstrate / inhibitor direction, not just membership
Listed above
Which drugs share a target with Silibinin, and which of those have an active Phase 3 trial?